Repare Therapeutics

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded by Daniel Durocher, Agnel Sfeir and Frank Sicheri on September 6, 2016 and is headquartered in Saint-Laurent, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded on September 6, 2016 and is headquartered in Saint-Laurent, Canada.

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

Repare Therapeutics Inc. (RPTX) Just Overtook the 20-Day Moving Average

The consensus price target hints at a 95.5% upside potential for Repare Therapeutics Inc. (RPTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Repare Therapeutics Inc. (RPTX)? Wall Street Analysts Think 95%

The mean of analysts' price targets for Repare Therapeutics Inc. (RPTX) points to a 106.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Can Repare Therapeutics Inc. (RPTX) Climb 106% to Reach the Level Wall Street Analysts Expect?

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 955% and 160.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Repare Therapeutics Inc. (RPTX) Q3 Earnings and Revenues Surpass Estimates

Repare Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

Repare Therapeutics' shares have lost roughly half their value over the past year. Roche's deal for ATR inhibitor camonsertib validated the company's SNIPRx and STEP2 platform technologies, a unique take on the emerging field of synthetic lethality.

Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma Partners

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2022. “The worldwide license and collaboration agreement we signed with Roche this quarter represents a major step in the broad global development and commercialization of camonsertib, and validates our strategy to build value into our pipeline by developing i

Repare Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

Virtus LifeSci Biotech Clinical Trials ETF

Day One Biopharmaceuticals

Kezar Life Sciences Inc

Lyell Immunopharma

Mirati Therapeutics

Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bargain hunting.

Biotech ETF Tops in June: 5 Stocks That Outperform

Repare Therapeutics is working in synthetic lethality, where big pharma has shown interest. They have some early data.

Repare Therapeutics: Interesting Gene Editing Company, But Miles To Go

For the most part, biotech stocks have taken a beating this year, along with the broader market. The Nasdaq Biotechnology.

Repare Therapeutics stock is down as insiders flock to buy the $30-million RPTX dip

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022 at 03:20 p.m. Pacific Time/ 6:20 p.m. Eastern Time in Rancho Palos Verdes, CA. A live webcast of the fireside chat can be accessed in the Investor s

Repare Therapeutics to Participate at the Goldman Sachs 43rd Annual Global Healthcare Conference

Repare Therapeutics Inc (NASDAQ: RPTX), a top clinical-stage precision oncology corporation, announced that it's executed a collaboration and worldwide license deal with Roche for both the commercialization and development of RP-3500 (also known as camonsertib). This new shot up the company's stock price by 25%.

Repare Therapeutics shares rise by 25% after it announced its collaboration deal with Roche

Repare Therapeutics (RPTX) signs a licensing agreement with Roche (RHHBY) to develop its lead candidate for solid tumor indications.

Repare (RPTX) Up 20% on Deal With Roche for Solid Tumor Drug

The company just announced a major collaboration with multinational pharmaceutical giant Roche.

Why Repare Therapeutics Stock Is Skyrocketing Today

Roche Holding AG

Shares of Repare Therapeutics Inc. RPTX, -4.68% jumped 24.5% in premarket trading on Thursday, the day after the company said it signed a worldwide licensing and collaboration agreement with Roche Holding AG ROG, +0.74% to develop and commercialize Repare's experimental tumor treatment. The drug, camonsertib, is being tested as a way to treat tumors with specific synthetic-lethal genomic alterations.

Roche, Repare's licensing deal includes milestone payments worth up to $1.2 billion

Shares of Repare Therapeutics Inc. were trading higher in Wednesday's after-hours session, following news the company entered a worldwide license and collaboration agreement with Roche ROG, -1.13% to develop and commercialize camonsertib.

Repare Therapeutics shares rise 18% after news of Roche deal

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib (also known as RP-3500), a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of tumors with speci

Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the virtual 2022 Guggenheim Synthetic Lethality Day on Monday, May 16, 2022 at 9:00 a.m. Eastern Time. A live webcast of the fireside can be accessed in the Investor section of the Company's website at https://ir.reparerx.com/news-an

Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022. “The first quarter was marked by significant progress in our RP-3500 program, including the comprehensive new dataset from the TRESR trial which was part of the featured oral presentation at the AACR conference this year, and that the United States Adopt

Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that preclinical data demonstrating inhibition of CCNE1-amplified tumor growth in vivo by selective inhibition of PKMYT1 using RP-6306, a first-in-class small molecule candidate targeting PKMYT1, were published in Nature. SNIPRx®, Repare's proprietary, genome-wide, CRISPR-based screening approach, was used to unco

Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification

Repare Therapeutics Inc. (RPTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Repare Therapeutics Inc. (RPTX) Stock Jumps 9.1%: Will It Continue to Soar?

Repare Therapeutics Inc (NASDAQ: RPTX) presented updated data from its ongoing Phase 1/2 TRESR trial of RP-3500 for solid tumors with specific synthetic-lethal genomic alterations. The data were featured at the AACR Annual Meeting included monotherapy Phase 1 (Module 1) results from.

Repare Therapeutics Shares Dip After Updated RP-3500 Data In Solid Tumors

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today presented updated data from its ongoing Phase 1/2 TRESR (Treatment Enabled by SNIPRx) clinical trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of solid tumors with specific synthetic-lethal genomic alterations including t

Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual Meeting

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it has been selected for an oral presentation of clinical data from its ongoing Phase 1/2 TRESR (Treatment Enabled by SNIPRx) trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase), as well as two additional poster presentations at the

Repare Therapeutics to Present New Clinical and Preclinical Data at the 2022 AACR Annual Meeting

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced it has been selected for an oral presentation of clinical data from its ongoing Phase 1/2 TRESR trial of RP-3500 and a poster presentation of initial discovery and validation data of the novel Synthetic L

Repare Therapeutics to Present Comprehensive Phase 1 Monotherapy Data From the Phase 1/2 TRESR RP-3500 Clinical Trial and SNiPDx Panel at the 2022 AACR Annual Meeting

News for Repare Therapeutics Stock (RPTX)